TAp73 expression is associated with an increased serine/glycine synthesis, production of NADPH and GSH in different cancer models, and glutaminase-2 (GLS-2) and glucose-6-phosphate-dehydrogenase (G6PD) metabolic enzymes have been described as direct TAP73 targets [40], [41], [42], [43]. Here, GLS2 is linked to cancer.